The Regulatory Desk
A small independent brief on how health products, clinic tools, and patient rules are actually policed — not how they are advertised. Posted on this site. Not mailed.
On the desk
FDA warning letter to BlephEx LLC
Letter dated June 3, 2026 · CMS 725861 · Center for Devices and Radiological Health
The Food and Drug Administration told BlephEx, LLC of Brentwood, Tennessee, to stop marketing three eyelid devices for uses the agency says fall outside the class I exemptions the firm has relied on. The public letter also describes quality-system failures, including more than 177 complaints that FDA says were never properly reviewed, and a 2019 finding that the agency calls a repeat.
The products named are a powered eyelid-cleaning sponge, a battery-powered electrolysis unit, and heated expression forceps. FDA asked the firm to cease the commercial distribution at issue. A warning letter is an administrative notice. It is not a court judgment.
Read the notes on letter 725861
The desks
Five beats. Three public-record notes each. The note is the link. There is no list to join.
FDA
Warning letters, and what the agency actually asked a firm to do
-
June 3, 2026
Three eyelid devices, 177-plus complaints, a repeat from 2019. The letter on this desk.
-
April 30, 2026
Defibrillators and MRI ventilators. CAPA coded as user error. A report nine months late.
-
January 23, 2026
Libre 3 released without finished-device accuracy testing after assembly and sterilization.
Devices & drugs
Clearance, exemption, labeling, and the lane a product was sold under
-
June 25, 2026
Sterile multi-use drugs, mold on caps, a repeat warning letter, Import Alert 66-40.
-
May 20, 2026
APAP labeled for multi-patient reuse it was never cleared for. Cloud software on a 2016 risk file.
-
September 26, 2025
Sold as a no-heat healing beam outside the infrared-lamp exemption. No design-history file.
Clinic software
What the chart, the alarm, and the billing row were built to do
-
June 12, 2026
A silence-alarms switch and “device-agnostic” inputs added after 510(k) clearance, with no new filing.
-
November 21, 2025
DOJ: a proprietary EMR billed every debridement as the surgical code. Allegations, then a check.
-
January 27, 2020
The EHR admitted it sold clinical-decision alerts to an opioid manufacturer. The file later cases read against.
Malpractice
Notice, coverage, and the gap between a device letter and a practice claim
-
Public-use file through June 30, 2026
Malpractice payments as statistics. Names stripped by statute. Not a query on a person.
-
NPDB Guidebook, Title IV
Payers report a payment for the benefit of a practitioner. A manufacturer letter does not start that clock.
-
Closing language in the CDRH letters on this desk
Federal contracts and export certificates may follow the letter. A clinic verdict does not.
Advocacy
What an open record will show, and what it will not
-
September 16, 2025
FDA’s patient-facing warning: smartwatch BP claims without authorization, product code DXN.
-
OII Electronic Reading Room
Inspection observations are posted. The firm’s reply usually is not, unless someone FOIAs it.
-
Public door, illustrated from letter 725861
Anyone can report. The BlephEx letter is what it looks like when the firm’s own file was empty.
Method
These notes start from public records: FDA letters, board minutes, court dockets, Justice Department announcements, and a firm’s own published materials. They stay inside those sources. A manufacturer letter is not a finding about any clinic’s day-to-day practice. Corrections are posted on the same page as the error.
Posted here
There is no mailing list on this site, no form to write in, and no demo. The notes are the product. A machine-readable feed is at feed.xml for anyone who already uses a reader. That feed does not collect an address.